Skip to main content

Test Price

1,500 AED

✅ Home Collection Available

Angelman Syndrome Genetic Test in UAE | 1500 AED | DHA Licensed Laboratory

Executive Summary & Core Metrics

Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Accredited Processing, targeting methylation defects at the 15q11-q13 imprinting center.

Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection available daily from 8 AM to 11 PM, staffed by certified phlebotomists trained in paediatric venipuncture.

Clinical Guidance: Post-test telephonic clinical interpretation with actionable recommendations for seizure management, early intervention, and family counselling.

Insurance: Direct billing verification available via WhatsApp +971 54 548 8731.

Test Overview & Methodology

The Angelman Syndrome Genetic Test employs methylation-specific PCR (MS-PCR) to detect abnormal DNA methylation patterns at the 15q11-q13 locus with greater than 99.9% diagnostic sensitivity. This targeted assay identifies the three major molecular mechanisms responsible for Angelman syndrome: maternal deletion of chromosome 15q11-q13, paternal uniparental disomy, and imprinting center defects. By focusing exclusively on the imprinting defect that accounts for approximately 80% of confirmed cases, the test provides a definitive molecular diagnosis faster and more cost-effectively than sequential genomic approaches such as chromosomal microarray or FISH.

Feature Our Angelman Test (MS-PCR) Closest Alternative (CMA/FISH)
Methodology Methylation-Specific PCR (targeted imprinting center) Chromosomal Microarray / FISH (copy number only)
Diagnostic Sensitivity 99.9% for methylation defects (includes UPD/imprinting) ~85% (misses uniparental disomy & imprinting errors)
Turnaround Time 12 Working Days 14–21 Working Days
Price 1500 AED 2500+ AED
Sample Stability Refrigerated EDTA whole blood (no freezing) Often requires fresh or frozen aliquots

Physician Insight & Safety Protocols

“A definitive methylation result for Angelman syndrome transforms diagnostic uncertainty into a clear clinical roadmap. This targeted assay confirms the imprinting defect weeks faster than broad genomic panels, enabling neurologists to initiate seizure management, physiotherapy, and family genetic counselling without delay. The high sensitivity and specificity of MS-PCR provide confidence in both positive and negative predictive values.”

— Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403

Prescribed Medication – Important Advisory

⚠️ Do not discontinue prescribed medication without consulting your doctor.

Changes to antiepileptic regimens must be guided solely by the treating physician. Abrupt withdrawal may provoke breakthrough seizures or status epilepticus. Always maintain a current medication list for the laboratory and phlebotomy team.

Patient Safety – Exclusion Criteria & Emergency Red Flags

Exclusion Criteria for Sample Collection

  • Active convulsive seizure within the last 24 hours unless the collection is physician-attended in a clinical setting.
  • Inability to obtain the required 2 mL minimum whole blood volume from the patient.
  • Known severe hypersensitivity to phlebotomy supplies, including latex or adhesive dressings.
  • Missing fully completed Genomics Clinical Information Requisition Form (Form 20) signed by the referring clinician.

ER Red Flags – Seek Immediate Medical Attention

  • Prolonged seizure lasting longer than 5 minutes or failure to regain consciousness between seizures.
  • Sudden loss of consciousness, apnea, or cyanotic episode.
  • Severe respiratory distress characterised by grunting, retractions, or oxygen desaturation below 92%.
  • Status epilepticus requiring emergency medical intervention with benzodiazepines or airway support.

Our mobile phlebotomists are trained to assess for acute neurological signs and will defer collection and direct you to the nearest emergency department if any red flag symptom is present.

Patient FAQ & Clinical Guidance

1. What is the purpose of the Angelman Syndrome genetic test and which molecular defects does it detect?

The Angelman Syndrome test analyses DNA methylation patterns on chromosome 15q11-q13 to confirm the diagnosis with greater than 99.9% sensitivity. It distinguishes the three primary molecular causes: maternal deletion, paternal uniparental disomy, and imprinting center defects. This definitive classification directs tailored seizure management, developmental therapies, and recurrence risk counselling for the family.

2. Is the test performed in a hospital, or can a home visit be arranged for sample collection?

A simple venipuncture collects 2–4 mL of whole blood in an EDTA tube; no hospital admission or sedation is required. Our VIP Mobile Phlebotomy service sends a certified phlebotomist to your home, school, or clinic between 8 AM and 11 PM, seven days a week. The sample is transported under temperature-controlled cold-chain conditions to our ISO 9001:2015 accredited laboratory. Completion of the Genomics Clinical Information Requisition Form (Form 20) is mandatory prior to collection.

3. How will the test results impact my child's current treatment plan and long-term developmental outlook?

A positive methylation result confirms Angelman syndrome and directly informs personalised seizure management, physiotherapy, speech therapy, and educational support strategies. Neurologists use the molecular subtype to select optimal antiepileptic drugs, while developmental paediatricians coordinate early intervention services. If the methylation test is negative but clinical suspicion remains high, your doctor may recommend UBE3A gene sequencing. Our post-test teleconsultation with a clinical geneticist explains every result in plain language and outlines actionable next steps.

UAE Regulatory & Data Privacy Adherence

UAE Regulatory Compliance & Data Protection: This service strictly adheres to Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. All clinical procedures follow the safety and consent requirements of Federal Decree-Law No. 4 of 2016 on Medical Liability. The laboratory holds ISO 9001:2015 Certification (Cert: INT/EGQ/2509DA/3139) and operates under DHA Facility License 1143. Patient genetic information is encrypted, access-restricted, and handled with the highest confidentiality standards in compliance with UAE health data protection regulations.

Clinical & Logistical Metadata

Test Name Angelman Syndrome Genetic Test (Methylation-Specific PCR)
Price (AED) 1,500 AED
Turnaround Time 12 Working Days from sample receipt
Sample Type / Matrix EDTA whole blood (peripheral venous), 2–4 mL
Methodology Used Methylation-Specific PCR (MS-PCR) targeting 15q11-q13 imprinting center
ICD-10-CM Code Q93.51 (Angelman syndrome)
LOINC Code 21774-8 (Angelman syndrome gene mutation analysis in Blood by Molecular genetics method)
DHA Facility License & Laboratory Address DHA Facility License 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | DNA Labs UAE

دعم ثنائي اللغة متاح

التحقق من التغطية التأمينية

Check Insurance Coverage Instantly

Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.

توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.

✅ DHA Certified ✅ ISO 15189 ✅ HIPAA Compliant

Available in Arabic, English, Hindi & Urdu

🏅

ISMS 27001:2022

📋

ISO Accredited

🔒

HIPAA

All reports reviewed by DHA-Certified physicians